A patient with COPD and asthma on Flovent (fluticasone propionate) 110 µg, albuterol (salbutamol) and Atrovent (ipratropium) has an Asthma Control Test score of 13; should Breztri (budesonide/glycopyrrolate/formoterol) be added?

Breztri is NOT appropriate for this patient - the primary issue is uncontrolled asthma, not COPD

This patient's ACT score of 13 indicates poorly controlled asthma, which is the dominant problem requiring immediate attention. Breztri (budesonide/glycopyrrolate/formoterol) is FDA-approved only for COPD maintenance treatment and is explicitly NOT indicated for asthma treatment 1. The current regimen lacks a long-acting bronchodilator, which is the critical missing component for asthma control.

Why Breztri is Inappropriate

The FDA label clearly states Breztri has a "Limitation of Use: Not indicated for the relief of acute bronchospasm or for the treatment of asthma" 1. Using a COPD-specific triple therapy for asthma management contradicts evidence-based guidelines and regulatory approval.

The Correct Approach for This Patient

Step 1: Optimize Asthma Treatment First

Upgrade to a long-acting beta-agonist (LABA) + ICS combination immediately:

• Replace Flovent 110 with an ICS/LABA combination (e.g., fluticasone/salmeterol or budesonide/formoterol)
• An ACT score of 13 (well below the control threshold of 20) indicates the need for step-up therapy according to asthma guidelines
• Continue albuterol as rescue medication

Step 2: Address the COPD Component

For the COPD aspect, transition from short-acting to long-acting anticholinergic:

• Replace Atrovent (ipratropium - short-acting) with a long-acting muscarinic antagonist (LAMA) like tiotropium
• Guidelines strongly recommend LAMA over short-acting muscarinic antagonists for moderate-to-severe COPD (Grade 1A recommendation) 2
• LAMAs reduce both moderate and severe exacerbations more effectively than short-acting agents 2

Step 3: Consider Triple Therapy ONLY After Asthma Control

If symptoms remain uncontrolled after optimizing asthma treatment AND the patient has:

• Documented COPD with FEV1 <50% predicted
• History of ≥2 exacerbations per year
• Persistent symptoms despite dual therapy

Then consider triple therapy, but use an asthma-appropriate regimen - not Breztri.

Key Clinical Pitfalls to Avoid

1. Don't confuse asthma-COPD overlap syndrome (ACOS) management with pure COPD treatment - European guidelines recommend ICS + LABA as minimum therapy for ACOS, not COPD-specific triple therapy 3

2. Don't add triple therapy without first establishing adequate dual therapy - The current regimen with short-acting agents represents under-treatment of both conditions

3. Don't ignore the ACT score - A score of 13 demands immediate asthma treatment intensification before considering any COPD-specific interventions

Evidence-Based Rationale

The 2023 Canadian Thoracic Society guidelines support triple therapy (LAMA/LABA/ICS) for COPD patients at high exacerbation risk 4, and the 2017 GOLD guidelines recommend LABA/LAMA combinations for Group D COPD patients 5. However, these recommendations apply to COPD-predominant disease, not poorly controlled asthma.

For patients with both conditions, the 2015 ACCP/CTS guidelines note that combination ICS/LABA therapy improves lung function and reduces exacerbations 2, but emphasize starting with appropriate dual therapy before escalating to triple therapy.

The pneumonia risk with ICS-containing regimens (4% increased risk noted in meta-analyses 2) must be weighed against benefits, but this consideration comes AFTER establishing asthma control with appropriate ICS/LABA therapy.